Ultragenyx Pharmaceutical Inc. Files 2024 10-K
Ticker: RARE · Form: 10-K · Filed: Feb 19, 2025 · CIK: 1515673
| Field | Detail |
|---|---|
| Company | Ultragenyx Pharmaceutical Inc. (RARE) |
| Form Type | 10-K |
| Filed Date | Feb 19, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-K, pharmaceutical, financials, collaboration
Related Tickers: KYKOF
TL;DR
UGNX 2024 10-K is in. Full year financials and biz updates out.
AI Summary
Ultragenyx Pharmaceutical Inc. filed its 2024 10-K on February 19, 2025, reporting its financial performance for the fiscal year ending December 31, 2024. The company, headquartered in Novato, CA, operates in the pharmaceutical preparations sector. Key financial details and operational aspects for the year are outlined in this comprehensive filing.
Why It Matters
This filing provides investors and stakeholders with a detailed overview of Ultragenyx's financial health, strategic initiatives, and risk factors for the fiscal year 2024, crucial for understanding the company's performance and future outlook.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, Ultragenyx faces inherent risks related to drug development, regulatory approvals, market competition, and intellectual property.
Key Numbers
- 2024-12-31 — Fiscal Year End (Reporting period for the 10-K)
- 2025-02-19 — Filing Date (Date the 10-K was submitted to the SEC)
Key Players & Entities
- Ultragenyx Pharmaceutical Inc. (company) — Filer of the 10-K
- 2024-12-31 (date) — Fiscal year end
- 2025-02-19 (date) — Filing date
- Novato, CA (location) — Company headquarters
- Kyowa Kirin (company) — Mentioned in relation to a collaboration
FAQ
What is the primary business of Ultragenyx Pharmaceutical Inc. as stated in the filing?
Ultragenyx Pharmaceutical Inc. is primarily engaged in the pharmaceutical preparations industry, as indicated by its SIC code [2834].
When did Ultragenyx Pharmaceutical Inc. file its 10-K report for the fiscal year 2024?
The 10-K report for the fiscal year ending December 31, 2024, was filed on February 19, 2025.
Where is Ultragenyx Pharmaceutical Inc. headquartered?
Ultragenyx Pharmaceutical Inc. is headquartered at 60 Leveroni Court, Novato, CA 94949.
What is the SEC file number for Ultragenyx Pharmaceutical Inc.'s 10-K filing?
The SEC file number for this 10-K filing is 001-36276.
Does the filing mention any specific collaborations or agreements?
Yes, the filing references a 'Kyowa Kirin Collaboration' under 'License Agreement Terms'.
Filing Details
This Form 10-K (Form 10-K) was filed with the SEC on February 19, 2025 regarding Ultragenyx Pharmaceutical Inc. (RARE).